Table 2.
Comparative analyses of variables potentially associated with response phenotype to biologics.
| Adalimumab (n = 58) | Infliximab (n = 68) | Vedolizumab (n = 39) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| R (n = 33) | NR (n = 25) | P | R (n = 45) | NR (n = 23) | P | R (n = 19) | NR (n = 20) | P | |
| Age at UC diagnosis, mean years (SD) | 40.7 (15.9) | 35.5 (13.5) | .252 | 35.0 (14.7) | 36.8 (16.0) | .636 | 36.8 (18.6) | 39.9 (19.2) | .444 |
| Age at treatment onset, mean years (SD) | 47.3 (16.3) | 43.9 (14.1) | .413 | 40.4 (14.7) | 43.3 (15.2) | .454 | 45.8 (21.7) | 45.5 (17.9) | .960 |
| Sex, n (%) | |||||||||
| Male | 20(60.6) | 13 (52.0) | .597 | 30 (66.7) | 11 (47.8) | .191 | 9 (47.4) | 12 (60.0) | .527 |
| Female | 13 (39.4) | 12 (48.0) | 15 (33.3) | 12 (52.2) | 10 (52.6) | 8 (40.0) | |||
| Active tobacco use, n (%)a | 4 (12.5) | 1 (4.5) | .638 | 5 (11.4) | 4 (18.2) | .467 | 2 (11.1) | 4 (22.2) | .658 |
| Active alcohol use, n (%)a | 21 (65.6) | 10 (43.5) | .168 | 22 (50.0) | 11 (47.8) | 1.000 | 11 (61.1) | 8 (42.1) | .330 |
| Extent at diagnosis, n (%)a | |||||||||
| E1—Proctitis | 7 (25.0) | 4 (16.7) | .285 | 4 (9.8) | 4 (18.2) | .248 | 3 (21.4) | 2 (11.1) | .175 |
| E2—Left-sided colitis | 9 (32.1) | 13 (54.2) | 18 (43.9) | 5 (22.7) | 7 (50.0) | 5 (27.8) | |||
| E3—Pancolitis | 12 (42.9) | 7 (29.2) | 19 (46.3) | 13 (59.1) | 4 (28.6) | 11 (61.1) | |||
| Prior treatment, n (%)b | |||||||||
| No prior exposure | 27 (81.8) | 21 (84.0) | 1.000 | 38 (84.4) | 16 (69.6) | .160 | 9 (47.4) | 8(40.0) | .909 |
| One prior exposure | 6 (18.2) | 4 (16.0) | 6 (13.3) | 4 (17.4) | 7 (36.8) | 9 (45.0) | |||
| Two prior exposure | 0 | 0 | 1 (2.2) | 3 (13.0) | 3 (15.8) | 3 (15.0) | |||
| CRP >5mg mL−1 at baseline, n (%)c | 9 (33.3) | 8 (44.4) | .537 | 17 (58.6) | 8 (47.1) | .545 | 4 (40.0) | 12 (85.7) | .032 |
| Dose optimization, n (%) | 22 (66.7) | 22 (88.0) | .116 | 38 (84.4) | 18 (78.3) | 1.000 | 8 (42.1) | 15 (75.0) | .096 |
| Co-induction with corticosteroids, n (%) | 13 (39.4) | 8 (33.3) | .782 | 15 (33.3) | 11 (47.8) | .296 | 3 (18.8) | 7 (36.8) | .285 |
| Concomitance with corticosteroids, n (%) | 20 (60.6) | 13 (59.1) | 1.000 | 24 (53.3) | 20 (87.0) | .007 | 6 (35.3) | 14 (73.7) | .042 |
| Co-induction with Immunosuppressant, n (%) | 4 (12.1) | 2 (8.3) | 1.000 | 13 (28.9) | 5 (21.7) | .577 | 0 | 1 (5.3) | 1.000 |
| Hospitalization for UC, n (%)c | 2 (6.1) | 1 (4.0) | 1.000 | 8 (17.8) | 6 (26.1) | .527 | 3 (15.8) | 1 (5.0) | .342 |
P-values under the specified threshold were typed using bold text.
Abbreviations: CRP, C-reactive protein; NR, non-responder; R, responder; SD, standard deviation; UC, ulcerative colitis.
Proportion calculated on total available data.
Includes exposure to golimumab, tofacitinib, ustekinumab, and the 3 studied molecules.
Within 3 months prior to agent initiation.